Cardiac Safety Concerns Halt Aardvark's Phase 3 Prader-Willi Trial
AARD has more than doubled off its 52-week low of $4.88 on light trading volume (0.3× avg).
Summary
Aardvark Therapeutics has voluntarily paused its Phase 3 HERO trial for ARD-101, a lead compound for Prader-Willi Syndrome, due to reversible cardiac observations identified during routine safety monitoring in a healthy volunteer study. This significant setback introduces substantial uncertainty and delays for the clinical-stage biopharmaceutical company, as ARD-101 is a key pipeline asset. The company will conduct a comprehensive data review and no longer expects to announce topline data in Q3 2026, with further guidance anticipated in Q2 2026. Traders will be closely watching for the outcome of the data review and any revised development plans, as the viability of this late-stage program is now in question, potentially impacting the company's valuation.
At the time of this announcement, AARD was trading at $12.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $271.9M. The 52-week trading range was $4.88 to $17.94. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.